| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8814360 | Biological Psychiatry | 2017 | 49 Pages |
Abstract
The results of this trial, the first evaluating a CRF1 receptor antagonist for the treatment of PTSD, combined with other negative trials of CRF1 receptor antagonists for major depressive disorder, generalized anxiety disorder, and social anxiety disorder, suggest that CRF1 receptor antagonists lack efficacy as monotherapy agents for these conditions.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Boadie W. Dunlop, Elisabeth B. Binder, Dan Iosifescu, Sanjay J. Mathew, Thomas C. Neylan, Julius C. Pape, Tania Carrillo-Roa, Charles Green, Becky Kinkead, Dimitri Grigoriadis, Barbara O. Rothbaum, Charles B. Nemeroff, Helen S. Mayberg,